nach oben

European Journal of Medical Research

Erschienen in:

01.12.2010 | Research

Bendamustine in patients with relapsed or refractory multiple myeloma

verfasst von: M Michael, I Bruns, E Bölke, F Zohren, A Czibere, N N Safaian, F Neumann, R Haas, G Kobbe, R Fenk

Erschienen in: European Journal of Medical Research | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

In patients with multiple myeloma, bendamustine monotherapy is effective as 1^st and 2^nd line therapy. However, data for patients with advanced multiple myeloma is rare.

Methods

In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma by means of case research, who have been treated at our institution with bendamustine as salvage therapy. After in median 2 lines of prior therapy (range:1-5) patients received in median 3 (range: 1-10) cycles of bendamustine. Bendamustine dosage was 80-150 mg on day 1+2 of a monthly cycle. Bendamustine was administered as monotherapy in 39% of patients, whereas 61% received concomitant steroids.

Results

Toxicity was mild to moderate. Response rates were as follows: 3% vgPR, 33% PR, 18% MR, 26% SD and 20% PD. The median event-free and overall survival were 7 and 17 months, respectively.

Conclusions

In conclusion, in patients with advanced multiple myeloma bendamustine is effective and associated with mild toxicity. Therefore, the role of bendamustine in patients with multiple myeloma should be investigated in further clinical trials.

Child JA, Morgan GJ, Davies FE, Owe RG, Bell SE, Hawkins K, et al.: High-dose chemotherapy with haematopoetic stem-cell rescue for multiple myeloma. New England Journal of Medicine 2003,348(19):1875–1883. 10.1056/NEJMoa022340PubMedCrossRef

Attal M, Haroisseau JL: Standard therapy versus autologous transplantation in multiple myeloma. Hematology/Oncology Clinics of North America 1997,11(1):133–146. 10.1016/S0889-8588(05)70419-6PubMedCrossRef

Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al.: Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine 2003,349(26):2495–2502. 10.1056/NEJMoa032290PubMedCrossRef

Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C, et al.: Highdose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. British Journal of Haematology 2005,130(4):588–594. 10.1111/j.1365-2141.2005.05641.xPubMedCrossRef

Kleeberg L, Morgera S, Jacob C, Hocher B, Schneider M, Peters H, et al.: Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy. European Journal of Medical Research 2009,12(2):47–54.CrossRef

Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, Von Lilienfeld M, Orlopp K, Schmidt-Wolf I, Gorschlüter M: A systematic review of phase-II-trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. British Journal of Haematology 2005, 584–593.

Dimopoulos M, Spencer A, Attal M, Miles Prince H, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnycky M, Yu Z, Patin J, Zeldis JB, Knight RD: Lenalidomide plus Dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine 2007,357(2):2123–2132. 10.1056/NEJMoa070594PubMedCrossRef

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al.: Bortezomib in relapsed, refractory myeloma. New England Journal of Medicine 2005,352(24):2487–2498. 10.1056/NEJMoa043445PubMedCrossRef

Leon LM, Bailey B, Reifert J, Niemeyer C, Bendall H, Dauffenbach L, et al.: SDX-105 (Bendamustine), a clinically active antineoplastiv agent opsesses a unique mechanism of action. Blood 2003,102(11):640.

10.

Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S: Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996,7(4):415–421. 10.1097/00001813-199606000-00007PubMedCrossRef

11.

Barman Balfour JA, Goa KL: Bendamustine. Drugs 2001, 61: 631–638. (8) 10.2165/00003495-200161050-00009CrossRef

12.

Schrijvers D, Vermorken JB: Phase I studies with bendamustine: an update. Seminars in oncology 2002,29(4 Suppl 13):15–18. 10.1053/sonc.2002.34874PubMedCrossRef

13.

Gandhi V: Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Seminars in oncology 2002,29(4 Suppl 13):4–11. 10.1053/sonc.2002.34872PubMedCrossRef

14.

Forero-Torres A, Saleh MN: Bendamustine in Non-Hodgkin lymphoma: the double-agent that came from the cold war. Clinical lymphoma & myeloma 2007,8(Suppl 1):S13-S17.CrossRef

15.

Rummel MJ, et al.: Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 2007, 110: 385.

16.

Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagz RH, Oliver JW, Cheson BD: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. Journal of Clinical Oncology 2008,26(2):204–210. 10.1200/JCO.2007.12.5070PubMedCrossRef

17.

Kahl B, et al.: Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 2007, 110: 1351.

18.

Aivado M, Schulte K, Henze L, Burger J, Finke J, Haas R: Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Seminars in oncology 2002,29(4 Suppl 13):19–22. 10.1053/sonc.2002.34875PubMedCrossRef

19.

Cheson BD, Rummel MJ: Bendamustine: Rebirth of an old drug. Journal of Clinical Oncology 2009,27(9):1492–1501. 10.1200/JCO.2008.18.7252PubMedCrossRef

20.

Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R: Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATMChk2-Cdc25A and ATM-p-53-p21-pathways. Journal of Cancer Research and Clinical Oncology 2008,134(2):245–253.PubMedCrossRef

21.

Poenisch W, Niederwieser D: Bendamustine in the treatment of multiple myeloma: results and future perspectives. Seminars in oncology 2002,29(4 Suppl 13):23–26. 10.1053/sonc.2002.34876CrossRef

22.

Lonial S: Multiple Myeloma: Noval approaches for relapsed disease. Clinical Lymphoma Myeloma 2007,8(Suppl 1):18–23.CrossRef

23.

Poenisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, et al.: Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomized phase III study of the East German study group of hematology and oncology (OSHO). Journal of Cancer Research and Clinical Oncology 2006,132(4):205–212. 10.1007/s00432-005-0074-4CrossRef

24.

Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H: The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005,90(9):1287–1288.PubMed

25.

Poenisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U, Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, Haas A, Kreibich U, Niederwieser D, for the East German Study Group of Haematology and Oncology (OSHO): Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. British Journal of Hematology 2008,143(2):191–200. 10.1111/j.1365-2141.2008.07076.xCrossRef

26.

Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G: Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leukemia & lymphoma 2007,48(12):2345–2351. 10.1080/10428190701694194CrossRef

27.

Hrusivsky I, Heidtmann HH: Combination therapy of bortezomib with low-dose bendamustine in elderly patients with advanced multiple myeloma. Blodd 2005. ASH Annual Meeting Abstracts 106:Abstract 5122

28.

Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al.: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoetic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology 1998,102(5):1115–1123. 10.1046/j.1365-2141.1998.00930.xPubMedCrossRef

29.

Attal M, et al.: The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma (MM). Combined results ofthe IFM 99 trials. New England Journal Of Medicine 1996.

30.

Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez-Martínez R, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF: Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. Journal of Clinical Oncology 2008,26(35):5775–5782. 10.1200/JCO.2008.17.9721PubMedCrossRef

31.

Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Liesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC: Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British journal of haematology 2008,143(4):537–540.PubMed

32.

Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosiñol L, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Boral AL, Esseltine DL, Anderson KC, Bladé J: The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British journal of haematology 2008,143(1):6–53.CrossRef

33.

Hussein MA, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, Andresen S, Karam MA, Reed J, Faiman B, Kelly M, Walker E: Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006,81(7):889–895. 4 10.4065/81.7.889PubMedCrossRef

34.

Büssing A, Fischer J, Haller A, Heusser P, Ostermann T, Mathiessen PF: Validation of the brief multidimensional life satisfaction scale in patients with chronic diseases. European Journal of Medical Research 2009,14(4):171–177. 10.1186/2047-783X-14-4-171PubMedCentralPubMedCrossRef

35.

Büssing A, Girke M, Heckmann C, Schad F, Ostermann T, Kröz M: Validation of the self regulation questionnaire as a measure of health in quality of life research. European Journal of Medical Research 2009,14(5):223–227. 10.1186/2047-783X-14-5-223PubMedCentralPubMedCrossRef

Titel: Bendamustine in patients with relapsed or refractory multiple myeloma
verfasst von: M Michael
I Bruns
E Bölke
F Zohren
A Czibere
N N Safaian
F Neumann
R Haas
G Kobbe
R Fenk
Publikationsdatum: 01.12.2010
Verlag: BioMed Central
Erschienen in: European Journal of Medical Research / Ausgabe 1/2010
Elektronische ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-15-1-13

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

HIV-induced immune activation - pathogenesis and clinical relevance. Summary of a workshop organised by the German AIDs Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008

Spinning around or stagnation - what do osteoblasts and chondroblasts really like?

Absolute count of T and B lymphocyte subsets is decreased in systemic sclerosis

Use of marginal organs in kidney transplantation for marginal recipients: too close to the margins of safety?

DNA methylation of the RIZ1 tumor suppressor gene plays an important role in the tumorigenesis of cervical cancer

Intensified surveillance after surgery for colorectal cancer significantly improves survival